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ORIGINAL ARTICLE
The oral HDAC inhibitor pracinostat (SB939) is efﬁcacious
and synergistic with the JAK2 inhibitor pacritinib (SB1518)
in preclinical models of AML
V Novotny-Diermayr, S Hart, KC Goh, A Cheong, L-C Ong, H Hentze, MK Pasha, R Jayaraman, K Ethirajulu and JM Wood
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly patients,
hence the unmet medical need for effective therapies with less toxicity and better tolerability. Inhibitors of FMS-like tyrosine
kinase 3 (FLT3), JAK2 and histone deacetylase inhibitors (HDACi) have been tested in clinical studies, but showed only moderate
single-agent activity. High efﬁcacy of the HDACi pracinostat treating AML and synergy with the JAK2/FLT3 inhibitor pacritinib
is demonstrated. Both compounds inhibit JAK-signal transducer and activator of transcription (STAT) signaling in AML cells with
JAK2
V617F mutations, but also diminish FLT3 signaling, particularly in FLT3-ITD (internal tandem duplication) cell lines. In vitro,
this combination led to decreased cell proliferation and increased apoptosis. The synergy translated in vivo in two different AML
models, the SET-2 megakaryoblastic AML mouse model carrying a JAK2
V617F mutation, and the MOLM-13 model of FLT3-ITD-driven
AML. Pracinostat and pacritinib in combination showed synergy on tumor growth, reduction of metastases and synergistically
decreased JAK2 or FLT signaling, depending on the cellular context. In addition, several plasma cytokines/growth factors/
chemokines triggered by the tumor growth were normalized, providing a rationale for combination therapy with an HDACi
and a JAK2/FLT3 inhibitor for the treatment of AML patients, particularly those with FLT3 or JAK2 mutations.
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INTRODUCTION
Acute myeloid leukemia (AML) is a myeloid malignancy character-
ized by deregulated proliferation, increased self-renewal and
limited differentiation of myeloid blasts. AML is typically
diagnosed in elderly patients and the standard of care treatment
is mainly chemotherapy. Most patients relapse and perish from
the disease or the associated complications. Aggressive che-
motherapeutic treatment can only be used in a minority of
patients; hence, there is a great medical unmet need, for effective
targeted therapy with less toxicity and better tolerability.
1
Histone deacetylase inhibitors (HDACi) are a class of drugs that
alter the acetylation status of both histone and non-histone
proteins, thereby affecting a range of cellular functions of
neoplastic cells, such as transcriptional activation, cell prolifera-
tion, immune responses, cell differentiation, survival and angio-
genesis.
2,3 HDACis, including pracinostat (SB939), have shown
clinical activity in AML and myelodysplastic syndrome, as well as
myeloproliferative neoplasms (MPNs); however, it seems that
efﬁcacy as a single agent is only moderate.
4–6
JAK2 mutations or fusion proteins leading to constitutive
activation of JAK2 have long been known to have a role in MPNs
and leukemia.
7,8 JAK2 inhibitors, such as pacritinib (SB1518),
9 an
oral inhibitor currently in Phase II clinical studies, as well as other
JAK2 inhibitors show signiﬁcant efﬁcacy in treating MPNs,
10–12
reducing the JAK-STAT (signal transducer and activator of
transcription) signaling, spleen size, JAK2
V617F mutation burden,
as well as levels of certain cytokines/growth factors relevant
in MPNs. Nuclear JAK2 has been reported to have a second,
epigenetic function that might contribute to leukemogenesis.
13,14
The JAK-family kinases were shown to cause phosphorylation of
Y41 on histone H3, displacing heterochromatin protein 1a from
its position bound to histone H3. Sustained displacement of
the heterochromatin protein 1a triggers increased expression
of oncogenic transcription factors, such as LMO2, enhanced
mitotic recombination, chromosomal disjunction and aneuploidy.
All these changes promote oncogenesis and are consistent with
the phenotypic consequences observed after constitutive JAK2
activation in hematological malignancies.
13,15
A mutation in the FMS-like tyrosine kinase 3 (FLT3), the FLT3
internal tandem duplication (ITD), causes constitutive active FLT3
signaling, leading to activation of the downstream STAT5. The
FLT3–ITDs are described in up to 35% of all AML patients,
16,17 and
a single FLT3–ITD is sufﬁcient to induce a myeloproliferative
phenotype, as shown in genetic mouse models,
18,19 demon-
strating the importance of mutated FLT3 in the pathogenesis of
acute leukemia.
The HDACi givinostat (ITF2357) has been reported to reduce
levels of total JAK2 as well as STAT5 in the JAK2
V617F mutant
cells.
20 In addition, the HDACi panobinostat and the JAK2/FLT3/
RET inhibitor TG101209 are reported to exert synergistic cyto-
toxic effects against cell lines carrying the JAK2
V617F mutation.
21
Another interesting recent observation is that HDACi selectively
target FLT3–ITD for degradation in AML cells.
22 In addition,
superior activity on AML cell apoptosis has been reported for a
combination of an HDACi and a FLT3 inhibitor.
23,24 On the basis of
these encouraging observations, we explored at multiple levels
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Pracinostat is an oral pan-HDACi with favorable pharmacoki-
netics
25 and good tolerability in patients,
26,27 which is currently
explored as a single agent in multiple Phase II clinical studies, for
solid tumors as well as myelodysplastic syndrome, AML and
myeloﬁbrosis. Pacritinib
9 is an oral JAK2/FLT3 kinase inhibitor, also
with favorable pharmacokinetics and good tolerability, which is
currently in Phase II clinical studies for myeloﬁbrosis and
lymphoma.
12 The studies described in this manuscript provide
a rationale for the combination of these two drugs as a treat-
ment for AML patients, especially those with either mutated
FLT3 or JAK2.
MATERIALS AND METHODS
Compounds
Pracinostat (SB939) as hydrochloride salt and pacritinib (SB1518) as citrate
salt were synthesized by SAI Advantium Pharma Ltd (Hyderabad, India). For
in vitro studies, drugs were dissolved in dimethyl sulfoxide (10mM stock);
for in vivo studies, the dosing solutions for oral gavage were prepared in
0.5% methylcellulose (w/v) and 0.1% Tween-80 in H2O (MC/Tween), stored
at 41C, and prepared freshly at least every week. All in vivo doses described
for pacritinib refer to the free base.
Cells
Cell lines used were obtained from either the American Type Culture
Collection (Manassas, VA, USA) or the Deutsche Sammlung von
Mikroorganismen und Zellkulturen (Braunschweig, Germany). SET-2,
KG-1, F36-P, HEL92.1.7, THP-1, MV4-11, MOLM-13, ML-2, ME-1, SH-2,
HL-60, MOLM-16, 32D, K562, KARPAS-1106P and RS4;11 cells were all
cultivated according to the vendor’s instructions, tested for mycoplasma
contamination (Mycoplasma Plus PCR Primer Set, Stratagene; Agilene
Technologies Inc., Santa Clara, CA, USA) and veriﬁed by STR proﬁling (John
Hopkins University, Baltimore, MD, USA). Granulocyte macrophage colony-
stimulating factor to supplement F-36P cell growth medium was obtained
from i-DNA Biotechnology (Singapore), fetal bovine serum was obtained
from PAA Laboratories GmbH (Pasching, Austria).
Primary AML cells
Peripheral blood mononuclear cells or bone marrow mononuclear cells
from AML patients were obtained from AllCells (Emeryville, CA, USA) and
ProteoGenex (Culver City, CA, USA) from a total of 16 patients. Cultivation,
expansion and analysis were carried out as described previously.
28
Cell proliferation assay and determination of in vitro synergy
Cells were seeded in 96-well plates at a predetermined optimal density (in
the log phase and rested for 2h) before drug treatment and then treated
for 48h with drug concentrations from 10mM to 1.5nM in 9 serial-dilution
steps with 0.1% solvent, and using the CellTiter-Glo Assay (Promega,
Madison, WI, USA), according to the manufacturer’s instructions, in a total
volume of 100ml. At least three independent experiments were performed
in triplicates. IC50 were determined using XLﬁt (IDBS, Guildford, UK). To
calculate the in vitro synergy of two drugs, they were combined at a
constant ratio, based on the individual drug’s IC50 concentrations, with the
highest doses used being 8  IC50 concentrations.
29 For sequential
treatments, cells were treated with drug 1 for 24h followed by a 24h
treatment with drug 2; simultaneous treatments were performed for 48h.
Synergy was determined using the CompuSyn software (v2007; ComboSyn
Inc., Paramus, NJ, USA). Combinatorial indices (CIs) were calculated
29 CIo1
(synergy), CI41 (antagonism) and CI¼1 (additive) for in vitro combinations.
Lysis and western blots
Cell lysis, protein quantiﬁcation and western blots were performed as
described previously.
20 Antibodies against pFLT3 Y591 (no. 3461), pSTAT3
Y705 (no. 9145), pJAK2 Y1007/1008 (no. 3776), STAT5 (no. 9310), and
cleaved poly-adenosine di-phosphate ribose polymerase N214 (no. 9541)
as well as horse-radish peroxidase linked secondary antibodies were from
Cell Signaling Technologies (Danvers, MA, USA). The antibodies against
pSTAT5 Y694 (no. 611965) and STAT3 (no. 610190) were obtained from BD
Biosciences (San Jose, CA, USA). The b-actin antibody (no. 2066) and the
FLT3 antibody were from Sigma Aldrich (St Louis, MO, USA) and Santa Cruz
Biotechnology (Santa Cruz, CA, USA), respectively. The LMO2 antibody
(no. 91652) was obtained from Abcam (Cambridge, MA, USA).
Subcutaneous animal models
Female BALB/c nude mice were obtained from the Biological Resource
Centre (Biopolis, Singapore), female SCID mice were purchased from
BioLASCO (Taipei, Taiwan) and female SCID/Beige mice were obtained
from Charles River Laboratories (Willmington, MA, USA). BALB/c nude mice
(BALB/cOlaHsd-Foxn1
nu) were 8–10 weeks of age; SCID mice (C.B-17/
IcrHantHsd-Prkdc
scid) 5–11 weeks of age, and SCID-Beige mice (C.B-17.Cg-
Prkdc
scidLyst
bg/Crl) were 9 weeks old. Standard protocols were followed, in
compliance with the National Institutes of Health and National Advisory
Committee for Laboratory Animal Research guidelines (IACUC approval no.
0800371).
For subcutaneous (s.c.) AML models, mice were implanted with 5 10
6
cells (or 1 10
7 for MV4–11 cells) in the right ﬂank. Cells were re-
suspended in 50ml serum-free growth medium, mixed 1:1 with Matrigel
(Cat no. 354248; BD Bioscience) and injected in a total volume of 100ml.
Tumor volumes were monitored using caliper measurements and volumes
calculated using the formula: tumor volume (mm
3)¼(w
2 l)/2 (w¼width
and l¼length in mm of the tumor xenograft). Pracinostat and pacritinib
were administered by per oral gavage in a volume of 10ml/kg if not
otherwise stated. Pracinostat was dosed at 25–125mg/kg either daily
or every other day. Pacritinib was dosed 50–150mg/kg daily or twice
daily. Tumors were excised on the last day of treatment, 3h post-dose.
In vivo synergy was determined using the Clarke’s CI (CCI) Equation:
30
CCI¼A/B (C/B D/B), and must be o0 to be synergistic, where A is the
average tumor measurement from the combination group; B, the average
measurement from the vehicle control; and C and D, the average measure-
ments from monotherapy 1 and 2, respectively. All statistical analyses were
performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
Orthotopic AML model
SCID mice (from Biological Resource Centre) were injected intravenously
with 1 10
7 HL-60 cells in 100ml serum-free medium. Mice were
monitored three times per week for signs of paralysis. A separate take-
rate control group was analyzed on day (d) 29 as previously described,
31
indicating a good take-rate. Treatment of the experimental group started 1
day later, on d30 after inoculation (before the ﬁrst mouse in this group
showed symptoms of paralysis). Blood counts were performed from tail
blood, using a ScilVet abc hematology analyzer (Scil Animal Care Company,
Gurnee, IL, USA) according to the manufacturer’s instructions. Statistical
analyses were performed using GraphPad Prism 5.
Pharmacokinetic analysis of pracinostat and pacritinib
The bioanalysis to detect levels of either pracinostat or pacritinib from 50ml
murine plasma was performed as described previously.
9,20 Two
independent experiments were performed, either in 16 weeks old
female BALB/c nude mice (BALB/cOlaHsd-Foxn1
nu) from Biological
Resource Centre (n¼3–5 per time point), or in 8–12 weeks old female
BALB/c mice (BALB/cOlaHsd) from Biological Resource Centre (n¼4 per
time point). Pharmacokinetic parameters were calculated by a non-
compartmental method using WinNonlin 5.2 software (Pharsight Corp.,
Sunnyvale, CA, USA).
Cytokine/growth factor analysis
Murine or human plasma samples were analyzed by Millipore Corp.
(Billerica, MA, USA) for cytokine/chemokine/growth factor measurements
using the Luminex xMAP technology. The Milliplex MAP Mouse Cytokine/
Chemokine panel (premixed 32-plex, MPXMCYTO-LIX) was used for mouse
samples.
RESULTS
Pracinostat inhibits JAK-STAT as well as FLT3-STAT5 signaling
Cells, expressing wild-type (wt) JAK2 (32D murine myeloid cells)
or mutant JAK2
V617F (HEL92.1.7 and SET-2) were treated with
pracinostat in concentrations ranging from 125–500nM for 24h,
and levels of pJAK2, JAK2, pSTAT5 and STAT5 were measured.
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pSTAT5 (Y694) levels, and also total JAK2 and STAT5 protein in
JAK2
V617F mutant cells (see Figure 1a). These proteins remained
unaffected in the JAK2 wt cells 32D and KARPAS 1106-P (Figure 1a
right hand panel and data not shown). To determine the effects
of pracinostat on cells with either mutated or wt FLT3, MV4-11
cells or MOLM-13 cells carrying FLT3 ITDs were compared
with RS4;11 cells with wt FLT3. In FLT3-ITD cell lines, pracinostat
led to a near-total ablation of pFLT3 (Y591) at 500nM in MV4-11
and MOLM-13 cells, respectively, with very steep dose response
(Figure 1b). There was a concomitant decrease in total FLT3
as well as pSTAT5, described to be a direct downstream substrate
of FLT3 in FLT3-ITD cell lines.
32 In RS4;11 cells, which express wt
FLT3, levels of pFLT3 and FLT3, and pSTAT5 were also reduced,
but to a lesser extent and more gradually with dose than in the
FLT3-ITD cell lines. In contrast to the FLT3-ITD cell lines, there was
no decrease in total STAT5; however, the levels of total STAT5 are
very low.
Pracinostat and pacritinib show in vitro synergy on STAT signaling
and apoptosis
To determine whether pacritinib, a JAK2/FLT3 kinase inhibitor,
combined with pracinostat would lead to even more pronounced
inhibition of STAT signaling and cause increased cell death in JAK2- or
FLT3-driven disease models, JAK2
V617F mutant cell lines were treated
simultaneously with pracinostat and pacritinib. As described previ-
ously, pacritinib treatment alone increased pJAK2 levels in the
JAK2
V617F cell lines,
9 whereas downstream pSTAT5 was decreased.
The combination of pacritinib and pracinostat completely abrogated
the JAK2-autophosphorylation in Set-2 cells (Figure 1c). The same
effect, although to a lesser extent, was observed in HEL92.1.7 cells.
Concurrently with the decrease in pSTAT5, there was an increase
in cleaved poly-adenosine di-phosphate ribose polymerase levels,
indicating enhanced cell death after the combination of pracinostat
and pacritinib. This was also more pronounced in SET-2 cells than
HEL92.1.7 cells (Figure 1c). The combination also increased efﬁcacy in
reducing levels of pFLT3 and total FLT3, as well as increasing cleaved
Figure 1. Pracinostat downregulates JAK and FLT3 signaling in JAK2
V617F and FLT-ITD cell lines, and shows synergy in combination
with pacritinib. (a–d) Western blot analyses from 25 or 50mg (pFLT3 and FLT3 blots only) of total cell lysate of the indicated cell lines with
JAK2
V617F, JAK2, or FLT3-ITD or FLT3 wt are shown. (a, b) Cells were treated with the indicated concentrations of pracinostat (SB939) for 24h.
(c, d) Cells were treated for 24h with pracinostat with pacritinib (SB1518) added in the indicated concentrations for the last 2h of incubation
before lysis.
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lines MV4-11 and MOLM-13 (Figure 1d). There was also a greater
reduction in the oncogenic transcription factor LMO2, suggesting
that pracinostat and pacritinib also might synergize on the
epigenetic level (bottom panel of Figure 1d) in FLT3-ITD cell lines.
Pracinostat potently inhibits proliferation of different AML
subtypes as a single agent and is synergistic with pacritinib
in JAK2
V617F or FLT3-ITD AML cell lines
AML cells are among the most sensitive cancer cells to HDAC
inhibition.
20 The IC50 on cell proliferation in a panel of 11 AML cell
lines ranged from 70–560nM, with the panel covering most subtypes
of AML according to the French–American–British classiﬁcation, with
t h ee x c e p t i o no fM 1a n dM 3( s e eF i g u r e2 a ) .P r i m a r yA M Lc e l l s ,
expanded from peripheral or bone marrow blasts in the presence
of FLT3 ligand, stem cell factor, interleukin (IL)-3 and IL-6 were
on average less potently inhibited, with mean IC50 values for the
different French-American-British (FAB) classiﬁcation types ranging
between 622nM and 1.5mM. Individual blasts had IC50 as low as
169nM a n do t h e r sa sh i g ha s2 . 2 mM (Figure 2b, Supplementary
Figures 1 and 2). Within the small number of cells and cell lines
tested, there was no clear trend for any AML subtype to be more
sensitive to HDAC inhibition than others. The two FLT3-ITD primary
AML blasts (Figure 2b, shaded gray) had similar sensitivity towards
pracinostat as the FLT3 wt blasts. For pacritinib, cell lines dependent
on either JAK2 or FLT3 signaling (such as SET-2, MV4-11 or MOLM-13)
were the most sensitive to JAK2/FLT3 inhibition, both on cell
proliferation as well as on the target biomarker levels (described
elsewhere
9). Similarly, primary AML blasts containing the FLT-3
ITD were amongst the most pacritinib-sensitive cells in cell
proliferation assays.
33 In vitro synergy was observed when
combining pracinostat and pacritinib (i.e., CIso1) in both FLT3-
ITD cell lines and JAK2
V617F cell lines, but not in HL-60 or KG-1
cells, which are wt for both genes. However, synergy was
observed for F-36P cells, which are wt for both JAK2 and FLT3,
but are fully dependent on JAK2 signaling. The best effects were
observed in FLT3-ITD cell lines when both drugs were
administered simultaneously, with CIs of 0.77 and 0.41 at a
combination of doses that effectively blocked 90% of cell
proliferation (ED90) for MOLM-13 and MV4-11, respectively
(Table 1). Weaker synergy was noted in JAK2
V617F cell lines when
pracinostat was administered 24h before pacritinib, with CIs of
0.95 and 0.81 at ED90, respectively, for SET-2 and HEL92.1.7 cells.
The addition of pacritinib before pracinostat was antagonistic in
all cell lines tested at ED90 (Table 1).
Pracinostat is efﬁcacious in various animal models of human AML
Pracinostat as a single therapy was tested in different mouse
models of human AML. Treatment of mice bearing MV4-11
xenografts with pracinostat (25 or 50mg/kg per day for 21 days)
induced signiﬁcant (Po0.001) inhibition of tumor growth (TGI), by
59 and 116%, respectively. Complete tumor regression was
observed in 6 out of 10 animals at the end of the treatment
after the 50-mg dose (Figure 3a). To determine the anti-tumor
efﬁcacy in a model that is less sensitive to pracinostat, based on
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Figure 2. Pracinostat potently inhibits cell proliferation in AML cell
lines and primary AML cells. (a)I C 50 of cell lines tested in 48h cell
proliferation assays (CellTiterGlo); FAB: French–American–British
classiﬁcation of AML cells. Results show mean±s.d. from at least
three rounds of experiments, each performed in triplicates.
(b) Primary AML blasts from 16 patients were expanded and then
treated on d12–d13 with dimethyl sulfoxide or pracinostat serially
diluted in nine steps from 10mM to 1.5nM for 48h. Results show
means from two rounds of blast expansion/proliferation assays.
Gray-shaded icons depict blast cells carrying the FLT3-ITD.
Table 1. In vitro combination of pracinostat (SB939) and pacritinib
(SB1518)
Cell line Sequence CI at
ED50±s.d.
CI at
ED90±s.d.
n
Simultaneously 0.89±0.1 0.77±0.1
MOLM-13 (FLT3 ITD) SB939 ﬁrst 1.49±0.3 1.48±0.4 2
SB1518 ﬁrst 1.50±0.1 1.32±0.0
Simultaneously 0.55±0.1 0.41±0.2
MV4-11 (FLT3 ITD) SB939 ﬁrst 0.72±0.1 0.55±0.3 2
SB1518 ﬁrst 1.69±0.5 2.49±1.3
Simultaneously 1.4±0.2 1.35±0.2
HL-60 SB939 ﬁrst 1.35±0.5 1.57±0.3 4
SB1518 ﬁrst 1.67±0.2 2.17±1.1
Simultaneously 1.6±0.2 1.7±0.1
KG1 SB939 ﬁrst 1.3±0.5 1.0±0.2 2
SB1518 ﬁrst 1.8±0.1 2.7±0.6
Simultaneously 0.91 1.27
SET-2 (JAK2mt) SB939 ﬁrst 1.13 0.95 1
SB1518 ﬁrst 0.98 1.41
Simultaneously 2.07±0.9 2.40±1.4
HEL92.1.7 (JAK2 mt) SB939 ﬁrst 0.99±0.0 0.81±0.1 2
SB1518 ﬁrst 2.12±1.0 2.30±0.7
Simultaneously 0.74±0.2 0.6±0.2
F36P (GM-CSFdep,
JAK2 wt)
SB939 ﬁrst 0.98±0.3 0.8±0.3 3
SB1518 ﬁrst 1.81±0.8 1.9±1.0
Abbreviations: CI, combinatorial indice; GM-CSF, granulocyte macrophage
colony-stimulating factor; mt, mutant; wt, wild type.
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treated with pracinostat at either 75 or 125mg/kg every other day
for a total of 17 days. Dose-dependent TGI (55%) was observed,
which was statistically signiﬁcant (Po0.01) for the higher dose.
Pracinostat was very well tolerated in both studies (maximum
body weight losses of 7 and 4.7%, respectively, in the MV4-11 and
HEL92.1.7 model). See Supplementary Table 1 for an overview of
the efﬁcacy in different models. To assess the efﬁcacy of
pracinostat in a more physiological relevant model, HL-60 cells
were engrafted orthotopically (via tail vein injection). Treatment
with 125mg/kg pracinostat in a thrice weekly schedule was
started once the disease was established on d30, (as measured by
ﬂuorescence-activated cell sorting analysis of human cell-surface
markers on HL-60 cells in the murine bone marrow and peripheral
blood, data not shown), but before the onset of the ﬁrst
symptoms, such as hind-leg paralysis. Pracinostat treatment led
to a 17-day delay of the disease onset and a 50% reduction
of death caused by progressive AML on study d24 (Figure 3c,
upper panel). White blood counts on d15 of the study were
six-fold elevated and lymphocyte counts three-fold elevated
in vehicle-treated animals compared with disease-free SCID
mice (i.e., mice that were not inoculated with HL-60 cells).
Pracinostat treatment led to a signiﬁcant (Po0.001) decrease
in blood counts, effectively normalizing blood counts to the
levels of disease-free mice, without signiﬁcantly reducing the
numbers of platelets at the same time. These data demonstrated
the efﬁcacy and good tolerability of pracinostat in an orthotopic
model of AML (Figure 3d).
Pracinostat and pacritinib are synergistic in two different AML
disease models
The SET-2 model of megakaryoblastic leukemia was chosen to
test the in vivo combination of pacritinib and pracinostat, as the
growth of this cell line has been shown to be dependent on the
JAK2-STAT5 signaling.
34 Pacritinib as a monotherapy, dosed at
150mg/kg twice daily (i.e., the maximum tolerated dose) led to a
61% TGI, whereas pracinostat dosed at 75mg/kg q.o.d (less than
half the maximum tolerated dose) inhibited tumor growth by 56%.
On the basis of tumor volume, the TGI of the drug combination
was 86% (Figure 4a). On the basis of tumor weight, monotherapy
led to 47 and 42.5% TGI for pacritinib or pracinostat, respectively
(Figure 4b), whereas the combination TGI by 75%, giving rise to a
CCI value of  0.06 (indicating synergy). Interestingly, several
infrequent, but obvious metastases, were found in the lymph
nodes of mice in each group, except in mice dosed with pacritinib
alone or the animals treated with the combination of both drugs
(data not shown). When analyzing tumors at the end of the study
after chronic treatment with either monotherapy or the drug
combination, pSTAT5 levels were decreased by about 50% by
pacritinib alone and by 75% by the combination treatment.
Pracinostat alone led to increased pSTAT5 levels compared with
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Figure 3. Pracinostat is efﬁcacious in two s.c. and an orthotopic model of AML. (a) Female BALB/c nude mice (n¼10 per group) were
inoculated with 1 10
7 MV4-11 cells s.c. into the right ﬂank, and treatment as indicated was started on study d9. (b) Female BALB/c nude mice
(n¼5 per group) were inoculated s.c. with 5 10
6 HEL92.1.7 cells, treatment was started on d18. (c) Female SCID mice (n¼6 per group) were
injected with 1 10
7 HL-60 cells intravenously and scored daily for symptoms of paralysis. Treatment with pracinostat (SB939) 125mg/kg
three times per week was initiated on d30, before the ﬁrst animal showed symptoms of paralysis. Daily disease scores are shown in (c); blood
counts of naive mice, vehicle- or pracinostat-treated mice are shown in (d). ‘Naive mice’ refers to age-matched SCID mice that were not
injected with HL-60 cells. Statistical signiﬁcance was determined using analysis of variance/Bonferroni, ***Po0.001 and **Po0.01 signiﬁcance
compared with vehicle-treated animals.
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the combination of pracinostat and pacritinib was also tested in
mice bearing FLT3-ITD-driven MOLM-13 s.c. xenografts. In vitro
data showed that the MOLM-13 cells were the most sensitive
to both pracinostat and pacritinib,
9 and that the synergy of
combination treatment was greater than in SET-2 cells (Table 1,
Figure 2a). Therefore, a lower dose of pacritinib was used
(50mg/kg daily) in combination with pracinostat (75mg/kg
q.o.d) for the in vivo study with MOLM-13. This MOLM-13
xenograft model is extremely aggressive, within 10 days after
cell injection when treatment was initiated, with mean tumor
volumes being 553mm
3. Tumors were excised on d7 of the
study (after 8 days of treatment) when the mean tumor volume
in the vehicle group was 2952mm
3 (and the average tumor
weight was 1770mg). Treatment with pracinostat or pacritinib
as a monotherapy led to a 19.2 and 14.7% reduction in tumor
weight, respectively, whereas the combination treatment reduced
the average tumor weight by 46.9%, to 940mg (Po0.001)
(Figure 4c), giving rise to a synergistic CCI of  0.16. Western
blot analysis of the tumors (harvested 3h post pacritinib
treatment) on d7 showed that both pacritinib and, to a lesser
extent, also pracinostat decreased levels of pSTAT5. Levels
of pFLT3 were only decreased marginally, but chronic treatment
with pacritinib alone increased expression total levels of FLT3
signiﬁcantly. In combination, pacritinib and pracinostat not only
normalized FLT3 levels, but also reduced pSTAT5 levels and nearly
abolished all pFLT3 (Figure 4d).
Many of the s.c. implanted tumors in this model metastasized
(to the lungs, the nearest breast fat-pad and/or the lymph nodes).
In the vehicle group, 9/12 mice had 1 or 2 metastases, some of
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Figure 4. Pracinostat combined with pacritinib is efﬁcacious and synergistic in vivo in two different models of human AML. Female SCID-beige
mice (n¼12 per group) were inoculated with 5 10
6 SET-2 cells and treatment was started on d33 post-implantation (a, b). For the
combination group, both pacritinib (SB1518) and pracinostat (SB939) were administered in half the volume (as a 20mg/kg solution) every
other day; when both compounds were given simultaneously, all other doses were given at 10mg/kg, at least 8h apart for 19 days (d0–d18).
There was one non-treatment-related death in the vehicle group on study d11 (gavaging error). Female SCID mice (n¼12 per group) were
inoculated with 5 10
6 Molm-13 cells (c, d). Treatment was started on d11, animals were dosed every other day for 8 days, in contrast to (a),
animals were dosed with pacritinib only daily (in the evenings), pracinostat dosing remained unchanged, all dosing was done in a 10mg/kg
solution. On the last day, mice were killed and excised tumors were weighed. The doses showing signiﬁcant TGI versus vehicle (on the last day
of the study) using analysis of variance/Dunnet’s post test, are indicated with **Po0.01 or ***Po0.001. (e) Tumors from the MOLM-13 efﬁcacy
study (c, d) were harvested on the last day 3h post pacritinib dosing and immediately lysed. Western blot analyses for pFLT3, FLT3, pSTAT5 and
b-actin are shown from the lysates of three randomly selected tumors from each treatment group of (c).
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obvious, individual metastases per mouse) were reduced by 60
and 50%, respectively, after single-agent treatment with pacritinib
or pracinostat, respectively (Figure 4e). In combination, metastatic
incidents were reduced by 90%, leading to a CCI of  0.1,
indicating that the combination was able to inhibit metastatic
spread synergistically. The pharmacokinetic parameters of praci-
nostat were similar after 14 days of co-administration with
pacritinib, with the concentration–time curve being nearly
identical on d1 and d14 (Figure 5a). The Cmax and AUC0-N of
pacritinib were increased approximately two-fold in Cmax and
approximately four-fold in AUC after chronic dosing in combina-
tion (Figure 5b). Pacritinib also exhibited a two-fold increase in
exposure following repeated dosing in toxicokinetic studies in
mice as single agent (data not shown). Therefore, the observed
in vivo synergy is unlikely because of a moderate increase in
pacritinib exposure in the combination study design.
Effects of pracinostat, pacritinib or the combination on
tumor-induced growth factors and cytokines/chemokines
HDACi as well as JAK2 inhibitors have been described to affect the
production of various growth factors, chemokines and cyto-
kines,
35–38 thereby inﬂuencing tumor growth. Plasma cytokine/
growth factor/chemokine levels in naive mice (without SET-2
xenograft), or xenografted mice treated with vehicle, pracinostat
or pacritinib alone, or a combination thereof, were analyzed using
multiplex analysis/enzyme-linked immunosorbent assay. SET-2
tumors caused the plasma levels of IL-6, IP-10, KC, MCP-1 and
MIP-1b to increase (Figure 6) compared with levels present in
naive mice (i.e., mice that were not inoculated with tumor cells).
Single-agent treatment with pacritinib or pracinostat led to the
normalization of IL-6, IP-10, KC and MIP-1a. A synergistic effect for
the combination of pacritinib or pracinostat was observed for the
chemokine MCP-1. Plasma levels of MCP-1 were elevated from 44
(in naive mice) to 168pg/ml in tumor-bearing mice. Pracinostat or
pacritinib as single agents reduced levels by 40 and 10%,
respectively. In combination, MCP-1 levels were reduced by 69%
(to 53pg/ml).
DISCUSSION
In this study, we show the efﬁcacy and tolerability of the pan
HDACi pracinostat in various in vitro and in vivo models of AML,
and show synergistic effects at multiple levels in combination with
the JAK2/FLT-3 inhibitor pacritinib in both the in vitro and in vivo
setting. We also explored the possible mechanisms for these
synergistic anti-tumor effects. Previously reported synergistic
effects of an HDACi combined with a JAK2 inhibitor was attributed
to impaired chaperone function of heat shock protein 90 by the
HDACi, promoting proteasomal degradation and depleting total
JAK2 levels.
21 FLT3 is another heat shock protein 90 client protein,
where mutant forms such as FLT3-ITD are more dependent on the
chaperone association than their wt counterpart.
39 In addition,
earlier studies have shown that HDAC inhibition depleted mRNA
levels of JAK2
V617F.
21 Therefore, not surprisingly, we have demon-
strated that pracinostat not only reduced JAK2/STAT5 protein
levels in cells bearing a JAK2 mutation, but also FLT3/STAT5 levels
in cells with a FLT-3 mutations (as seen in Figure 1). Recent studies
with the HDACi trichostatin A demonstrate that JAK2/STAT3
signaling was decreased by upregulation of the expression of
suppressors of cytokine signaling (SOCS) 1 and 3 genes.
40 A possible
direct effect of the HDAC inhibition on the phosphorylation of
JAK2, STAT5 and FLT3 was not investigated in this study.
SB939 showed potent inhibition predominantly in JAK2V617F-
or FLT3-ITD-harboring cell lines (Figure 2a). The cell line with the
lowest IC50 of 70nM was HL-60, which carries an N-RAS mutation.
HDACi have been shown to block Ras-dependent signaling and
growth transformation.
41 Surprisingly, in HEL92.1.7 and MOLM-13
cells, the pracinostat IC50 on proliferation is lower than the IC50
on inhibition of JAK2 or FLT3-ITD protein levels, respectively.
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Figure 5. Pharmacokinetic analysis of pracinostat and pacritinib administered in combination. Female BALB/c nude mice were dosed with
150mg/kg pacritinib (SB1518) plus 75mg/kg pracinostat (SB939) simultaneously either once (‘day 1’) or for a total of 14 days (i.e., 7 doses of
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besides JAK2
V617F and FLT3-ITD by HDAC inhibition.
Pacritinib is an equipotent inhibitor of JAK2 and FLT3, which
is effective in reducing JAK2/STAT5 and FLT-3 JAK2 signaling
in JAK2 and FLT3 mutant cells, respectively.
33 The combination
of pracinostat and pacritinib led to synergistic effects with a
complete inhibition of downstream STAT5 signaling, an increased
efﬁcacy on cell proliferation and the induction of apoptosis.
In vitro combination studies in different cell lines with either wt or
mutant JAK2 or FLT3 also demonstrated synergy, mostly in cells
that carried the mutant protein. One exception was the F36-P
cell line. The growth of this cell line depends on exogenously
added granulocyte macrophage colony-stimulating factor,
42 which
signals exclusively via JAK2, making it a JAK2 wt-dependent cell
line. This indicates that synergy between a JAK2 inhibitor and an
HDACi might also work in cells that are fully dependent on JAK2
(wt) signaling. Consistent with this, similar in vitro synergy was
observed in the JAK2 wt SET-2 cells and F36-P cells but not in FLT3
mutant cell lines with the speciﬁc pan-JAK inhibitor ruxolitinib in
combination with pracinostat (data not shown).
LMO2 is a transcription factor involved in normal hemato-
poiesis, but also leukemogenesis that is overexpressed in many
AML cells.
43 Interestingly, LMO2 levels were downregulated
synergistically in MOLM-13 cells with pacritinib and pracinostat,
and may be a result of another synergistic interaction between
JAK2 and HDAC. Dawson et al.
43 demonstrate that JAK2 inhibi-
tion leads to lower levels of histone H3 Y41 phosphorylation
on the promoter of LMO2, whereas increasing the binding of
heterochromatin protein 1a at the same site, resulting in lower
expression of LMO2. JAK2 may have an epigenetic role in the
nucleus to inﬂuence the status of H3 acetylation. It has been
demonstrated previously that phosphorylation of H3 (on S10)
leads to increased efﬁciency of a subsequent H3 acetylation,
resulting in synergistic modiﬁcations of gene expression.
44
Pacritinib, as well as targeting JAK2, is a potent FLT3 inhibitor.
Our group has recently discovered that treatment of FLT3-ITD cells
with FLT3 inhibitors lacking JAK2 activity (e.g., ABT-869, VX-680 or
sunitinib), leads to an upregulation of JAK2 activity, causing
secondary resistance.
33 Therefore, although combinations of FLT3
inhibitors and HDACi have been described to show synergy in
vitro,
23,24 this combination without the additional JAK2 inhibition
could lead to resistance after chronic dosing and not show
enhanced efﬁcacy in the in vivo setting. This may explain why
none of the studies showing in vitro synergy reported any in vivo
synergy data. Pacritinib as a dual JAK2/FLT-3 inhibitor is therefore
ideally suited for a combination with an HDACi and superior to an
inhibitor that only affects FLT3 kinase without targeting other JAK
family kinases.
Although the combination of pracinostat and pacritinib showed
synergy in vitro, the synergy was greater in the in vivo setting in
both AML models tested. This indicates that there are additional
synergistic mechanisms that are only working in the whole animal
setting. One example is the synergistic effects observed on
metastases. In AML patients, leukemia cutis and extramedullary
involvement of organs such as the lungs are common. Respiratory
distress syndrome secondary to lung involvement causes a
signiﬁcant percentage of the morbidity/mortality associated with
AML.
45 Therefore, the synergy observed in reducing metastatic
sites in the animal model is certainly of great relevance for
AML patients. Interestingly, signiﬁcantly higher plasma levels of
MCP-1 were measured in untreated AML patients with extra-
medullary sites involved than in those with complete remission.
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Figure 6. Pracinostat and pacritinib have synergistic effects on AML-induced plasma cytokines/growth factors/chemokines. Plasma levels of a
panel of 32 cytokines/growth factors/chemokines were analyzed using the MAP Mouse Cytokine/Chemokine panel from Millipore. Plasma was
collected from SCID-beige mice bearing s.c. SET-2 tumors on d18, 3h post-dose, after chronic dosing with pacritinib and pracinostat from the
mice used in the efﬁcacy study described in Figure 4.
SB939 and SB1518 in AML
V Novotny-Diermayr et al
8
Blood Cancer Journal & 2012 Macmillan Publishers LimitedThis highlights the potential therapeutic beneﬁt with our obser-
vation that pracinostat and pacritinib synergistically decrease
MCP-1 plasma levels as well as metastatic occurrences. In both
models tested, chronic treatment with one drug alone led to the
increase of a signaling pathway. Pacritinib in the Molm-13 model
or pracinostat (Set-2 model) led to increased FLT3 or pSTAT5
levels, respectively, whereas the combination treatment in both
studies was most efﬁciently suppressing the signaling, indicating
that a combination treatment can overcome treatment-induced
resistance.
Effects of tumor-induced elevations of cytokine and chemokine
levels may be another mechanism for the synergy observed with
pracinostat and pacritinib. HDACi as well as JAK2 inhibitors have
been described to affect the production of various growth factors
and cytokines,
35–37 thereby inﬂuencing tumor growth. Manshouri
et al.
38 recently showed that resistance to JAK2-inhibitor treat-
ment of MPNs is mediated by cytokines produced by the bone
marrow stroma. Distinctly high levels of IL-6, FGF4 and CXCL10/
IP-10 were detected in co-cultures of stromal cells and SET-2 cells,
mediating resistance to the JAK2 inhibitor antiprimod. Although
SCID beige mice that lack B-cells, T-cells, as well as natural killer
cells, were used for the SET-2 AML model in our studies, high
circulating levels IL-6, IP-10, KC and MCP-1 were measured in
the tumor-bearing mice without drug treatment. Treatment with
pacritinib or pracinostat as single agents led to the normalization
of IL-6, IP-10, KC and MIP-1a, and a synergistic normalization of
MCP-1 levels was observed with the combination treatment.
Taken together, our studies demonstrated the synergistic
efﬁcacy of a combination of pracinostat and pacritinib in in vitro
and in vivo models of AML and offer mechanistic insights for this
synergy. These data provide a scientiﬁc rationale for the combina-
tion of pracinostat and pacritinib for advanced acute leukemia,
which warrants further exploration in a clinical trial.
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